VKOR Expression for Vitamin K-Dependent Protein Carboxylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for recombinant vitamin K-dependent protein expression in host cells are limited by the availability of reduced vitamin K, as vitamin K epoxide reductase (VKOR) activity is inhibited by warfarin, leading to undercarboxylation of these proteins, which are crucial for coagulation and other functions.
Innovation Solution
The use of nucleic acids encoding VKOR, specifically mammalian VKOR, is introduced into host cells to enhance the expression of vitamin K-dependent proteins by maintaining optimal VKOR activity, thereby ensuring sufficient vitamin K availability for carboxylation processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If warfarin is used to inhibit VKOR activity, then anticoagulation effect is achieved, but vitamin K availability decreases leading to reduced carboxylation efficiency
Solution Approach 1:
The patent introduces an alternative pathway using vitamin K2 (menaquinone) as an intermediary substrate that is not inhibited by warfarin. The VKOR enzyme can process vitamin K2 to regenerate reduced vitamin K, bypassing the warfarin-blocked pathway that uses vitamin K1 (phylloquinone). This mediator approach maintains carboxylation efficiency while preserving anticoagulation effects.
Solution Approach 2:
The patent changes the substrate parameter from vitamin K1 to vitamin K2, which has different chemical properties and is not affected by warfarin inhibition. This parameter change allows the VKOR enzyme to continue functioning and maintaining reduced vitamin K levels for carboxylation, even in the presence of warfarin.
2Quantity of substance
If reduced vitamin K availability occurs, then VKOR activity is compromised, but this leads to undercarboxylation of vitamin K-dependent proteins
Solution Approach 1:
The patent ensures continuous regeneration of reduced vitamin K through the VKOR enzyme acting on vitamin K2 epoxide. This continuous action maintains a steady supply of reduced vitamin K for carboxylation, preventing undercarboxylation of proteins even when vitamin K1 is depleted by warfarin inhibition.
Solution Approach 2:
The system uses the VKOR enzyme's inherent ability to reduce vitamin K epoxide to regenerate active vitamin K. By providing vitamin K2 as a substrate, the system enables self-service regeneration of reduced vitamin K without requiring external supplementation or intervention, maintaining carboxylation capacity autonomously.
3Quantity of substance
If vitamin K is depleted, then the vitamin K cycle is disrupted, but this prevents production of fully active vitamin K-dependent proteins
Solution Approach 1:
The patent introduces vitamin K2 into the system in advance as a reservoir substrate. This preliminary action ensures that when vitamin K1 is depleted by warfarin, the VKOR enzyme immediately has an alternative substrate to process, preventing disruption of the vitamin K cycle and maintaining protein production efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the productivity and carboxylation efficiency of vitamin K-dependent proteins, such as coagulation factors, by stabilizing VKOR expression and activity, leading to higher levels of fully active proteins.
Implementation Method 1
vitamin K epoxide must be converted back to vitamin K by vitamin K epoxide reductase (VKOR)
Implementation Method 2
the enzyme that accomplishes the Gla modification
Implementation Method 3
modification of multiple glutamic acid residues to γ-carboxyglutamate
Data Source
AI summary
The present invention relates to methods and compositions for improving the productivity of recombinant vitamin K dependent protein expression in host cells.